1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Adynxx, Inc.

Adynxx, Inc.

ADYX
Adynxx, Inc.US flagOther OTC
0.00
USD
- -
- -
581.00Market Cap
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
TTM
Revenue per Share
- -
- -
- -
49.4
22.2
23.22
13.69
15.11
19.63
31.68
34.96
2.82
2.7
0.17
Basic EPS, GAAP
-171.01
-157.22
-112.01
-26.04
-52.13
-175.55
-54.67
-188.55
-104.36
-67.69
-60.6
-35.94
-10.26
-2.47
Free Cash Flow per Basic Share
-53.15
-67.28
-60.6
-6.52
-29.74
-31.51
-22.87
-41.06
-55.91
-57.35
-41.25
-15.17
-11.83
-1.95
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-409.4
-551.84
-587.29
-23.42
-61.62
-221.84
-252.02
-374.64
-287.21
-249.85
-266.68
-209.72
-193.06
-13.11
Tangible Book Value per Share
-38.9
-19.22
88.28
96.37
66.92
32.05
15.55
94.68
57.52
-6.26
-13.89
-11.27
10.06
-3.13
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
4
Sales/Revenue/Turnover
- -
- -
- -
1
1
2
1
2
5
12
16
2
2
1
Operating Margin (%)
- -
- -
- -
-51.1
-206.02
-243.52
-398.53
-669.31
-514.82
-230.8
-165.91
-235.76
-238.99
-1,065.53
Depreciation Expense
- -
2
- -
1
1
1
1
1
1
3
4
5
2
- -
Net Income, GAAP
-5
-4
-4
-1
-3
-14
-5
-22
-25
-26
-28
-26
-8
-9
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-52.72
-234.83
-756.08
-399.24
-1,222.47
-531.65
-213.66
-173.33
-1,273.25
-379.83
-1,481.66
Working Capital
-1
-1
3
- -
2
- -
-1
9
15
23
-8
-9
8
-11
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
12
- -
- -
- -
1
Total Equity
-1
-1
3
7
25
14
12
14
23
52
32
16
8
-11
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'19
Jun'19
Sep'19
ST Debt
- -
8
9
LT Borrowings
- -
- -
- -
LT Finance Leases
1
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
6
6
Market Capitalization
14
5
5

Working Capital

FRC

•

in mil. unless spec.
Mar'19
Jun'19
Sep'19
Total Current Assets
8
2
3
Cash, Cash Equivalents & STI
8
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
11
14
Payables & Accruals
1
3
5
ST Debt
- -
8
9
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
42.18%
11.38%
-47.33%
Free Cash Flow
106.89%
34.76%
-10.52%
Net Income, GAAP
80.74%
-9.93%
-67.26%
Sales/Revenue/Turnover
- -
55.32%
9.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
4
1
- -
5
2
2018
1
1
- -
- -
2
2019
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
-13.67
-5.58
-3.41
- -
-35.94
2018
-7.13
-1.72
-0.91
- -
-10.26
2019
-1.04
-1.18
-0.33
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Richard Orr
Full Time Employees
6
Sector
Healthcare
Industry
Biotechnology
Address
100 Pine Street San Francisco CA United States of America 94111
IPO Date
Dec 18, 1998
CIK
0001054274
Website
adynxx.com
Similar Companies
Entera Bio Ltd. (ENTX)
Generex Biotechnology Corporation (GNBTQ)
Nuvectis Pharma, Inc. (NVCT)
RepliCel Life Sciences Inc. (REPCF)
Poseida Therapeutics, Inc. (PSTX)
EV Biologics, Inc. (YECO)
Business
Adynxx Inc (ADYX) is a clinical-stage biopharmaceutical company that develops and commercializes transcription factor decoy technologies for treating pain and inflammatory diseases; its AYX platform includes brivoligide (AYX1), an EGR1 transcription factor decoy in Phase II for reducing postoperative pain following surgeries such as total knee arthroplasty and mastectomy, and AYX2, a preclinical candidate for focal chronic pain including neuropathic and inflammatory types; the platform targets coordinated pathologic gene expression with non-opioid, disease-modifying therapeutics administered intrathecally as single doses. Founded in 2007 and headquartered in San Francisco, California, the company operates in the biotechnology sector, focusing on unmet needs in acute and chronic pain management for surgical patients at high risk of prolonged pain and opioid dependence; it targets U.S. markets with applications across multiple pain syndromes and collaborates on AI-driven discoveries for conditions like endometriosis. Adynxx completed a reverse merger with Alliqua BioMedical in May 2019, becoming Nasdaq-listed under its current name with former Adynxx holders owning 86% of the combined entity and shifting leadership to San Francisco; it secured a $5.7 million NIH grant from NIDA in 2019 for brivoligide's Phase II mastectomy study, with potential additional $9 million for Phase III; earlier, it closed a $16 million Series B financing led by TPG Biotech and received MTS Partners advisory for the Alliqua merger.